ESR1 and triple-negative breast carcinoma: PTX is considered as the first-line treatment drug in breast cancer (BC), especially in triple negative breast cancer (TNBC) [56], since this subtype of carcinoma is not sensitive to estrogen receptor positive breast cancer cell.